Dasatinib (Figure 1) is a Src, BCR-ABL, c-KIT, PDGFR-α and PDGFR-β, and ephrin receptor kinase blockers accepted by the Food and Drug Administration (FDA) for treating cases of Philadelphia chromosome positive leukemias (chronic myeloid leukemia; CML) [22,23]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.